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Our understanding of the molecular structures of amyloid fibrils that are associated with neurodegenerative
diseases, of mechanisms by which disease-associated peptides and proteins aggregate into fibrils, and of
structural properties of aggregation intermediates has advanced considerably in recent years. Detailed mo-
lecular structural models for certain fibrils and aggregation intermediates are now available. It is now well es-
tablished that amyloid fibrils are generally polymorphic at the molecular level, with a given peptide or protein
being capable of forming a variety of distinct, self-propagating fibril structures. Recent results from structural
studies and from studies involving cell cultures, transgenic animals, and human tissue provide initial evi-
dence that molecular structural variations in amyloid fibrils and related aggregates may correlate with or
even produce variations in disease development. This article reviews our current knowledge of the structural
and mechanistic aspects of amyloid formation, as well as current evidence for the biological relevance of
structural variations.Aberrant aggregation of certain peptides and proteins causes
many neurodegenerative diseases, including Alzheimer disease
(AD), Parkinson disease (PD), transmissible spongiform enceph-
alopathies (TSEs), Huntington disease, frontotemporal demen-
tia, and amyotrophic lateral sclerosis. The association of protein
aggregation with neurodegeneration motivates efforts in many
laboratories to elucidate the detailed molecular aspects of pro-
tein aggregation, including mechanisms and pathways of aggre-
gation and molecular structures of the aggregated states of the
relevant peptides and proteins.
The thermodynamic endpoints of protein aggregation (i.e., the
most stable self-assembled states under typical conditions) are
often filamentous assemblies called amyloid fibrils. Figure 1
shows examples of amyloid fibrils prepared in vitro. Amyloid
fibrils are inherently noncrystalline, insoluble materials, making
it difficult to determine their internal molecular structures by
traditional methods for high-resolution structure determination,
especially X-ray crystallography and multidimensional nuclear
magnetic resonance (NMR) spectroscopy. Over the past 10–15
years, progress has been made on the amyloid structure prob-
lem through the application of less traditional methods. One of
the most powerful methods for structural studies of amyloid
fibrils is solid state NMR (ssNMR), which means a set of NMR
techniques that are designed specifically for applications to
molecular assemblies that are not soluble and not necessarily
crystalline (Tycko, 2011). Other methods that have contributed
to recent progress include electron paramagnetic resonance
(EPR) (Margittai and Langen, 2008), electron microscopy (Golds-
bury et al., 2005; Serpell and Smith, 2000), cryo-electron micro-
scopy (cryo-EM) (Jime´nez et al., 1999; Meinhardt et al., 2009),
and hydrogen/deuterium exchange measurements (Kheterpal
et al., 2006; Lu¨hrs et al., 2005; Olofsson et al., 2007; Toyama
et al., 2007). In addition, X-ray crystallographic studies of pep-
tides in amyloid-like crystals have been quite valuable (Nelson632 Neuron 86, May 6, 2015 ª2015 Elsevier Inc.et al., 2005; Sawaya et al., 2007). Detailed structural information
at the molecular level is essential for a full understanding of the
amyloid formation process, for understanding of biological
effects arising from structural variations, and for the rational
development of compounds that can inhibit amyloid formation
(Estrada and Soto, 2007) or bind specifically to amyloid fibrils
for diagnostic imaging (Fleisher et al., 2011; Klunk et al., 2004).
A fundamentally important property of amyloid fibrils is their
ability to amplify and propagate their own structures by recruit-
ment of additional protein molecules from their surroundings.
Recent studies in a number of laboratories highlight the biomed-
ical significance of amyloid self-propagation in neurodegenera-
tive diseases (Eisele et al., 2010; Frost et al., 2009a; Iba et al.,
2013; Kfoury et al., 2012; Langer et al., 2011; Luk et al., 2012a,
2012b; Meyer-Luehmann et al., 2006; Sanders et al., 2014; Sto¨hr
et al., 2012, 2014; Volpicelli-Daley et al., 2011;Watts et al., 2014).
Amyloid self-propagation is a likely underlying mechanism for
the infectious nature of prion protein (PrP) particles in TSEs (Col-
linge and Clarke, 2007; Prusiner, 2013). Thus, the self-propaga-
tion of amyloid fibrils formed by proteins other than PrP is now
often called ‘‘prion-like’’ behavior.
If one accepts the definition that prions are disease-causing,
infectious, proteinaceous particles, then in vitro self-propagation
should not be called ‘‘prion-like.’’ Other issues regarding this
term, such as the distinction between propagation within a single
organism and transmission between organisms and the distinc-
tion between naturally occurring and artificially induced trans-
mission, have been discussed by others (Ashe and Aguzzi,
2013; Hardy and Revesz, 2012).
Polymorphism is another important property of amyloid fibrils
(Tycko, 2014). As shown in Figure 1 for the amyloid-b (Ab)
peptide associated with AD and the a-synuclein (a-syn) pro-
tein associated with PD, fibrils formed by a single peptide
or protein can be polymorphic, i.e., can exhibit multiple distinct
Figure 1. Polymorphism of Amyloid Fibrils and Aggregation
Intermediates, as Seen in Transmission Electron Microscope
Images with Negative Staining
(A) Synthetic Ab40 fibrils with ‘‘striated ribbon’’ morphologies.
(B) Synthetic Ab40 fibrils with ‘‘twisted’’ morphologies.
(C) Recombinant a-synuclein fibrils with striated ribbon (red arrow), twisted
(blue arrow), and rod-like (purple arrow) morphologies.
(D) Synthetic Ab40 aggregation intermediates with protofibrillar (orange
arrows) and nonfibrillar (green arrow) morphologies, prepared by quiescent
incubation of a 100 mMpeptide solution at 24C and pH7.4 for 36 hr. Scale bars
represent 200 nm.
Figure 2. Varieties of Cross-b Structures in Amyloid Fibrils
(A) An ‘‘in-register’’ parallel cross-b structure, in which b strand segments from
adjacent protein or peptide molecules align in parallel and with no shift of their
amino acid sequences (represented by the varying colors of carbon atoms)
relative to one another.
(B) An antiparallel cross-b structure. Silver bars indicated hydrogen bonds
between backbone carbonyl and backbone amide groups. The fibril growth
direction is indicated by the blue arrow.
(C–E) Schematic representations of cross-b structures that could be formed by
a peptide that contains two separate b strand segments, separated by a loop
or turn segment. Colors indicate successive copies of the same peptide
molecule. From left to right, the structures are a double-layered, in-register
parallel cross-b unit, a double-layered antiparallel cross-b unit, and a double-
layered antiparallel b-hairpin structure.
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ages. Although in principle amyloid polymorphs could merely
be different bundled arrangements of the same basic amyloid
‘‘protofilament’’ structure, in fact ssNMR measurements clearly
show that amyloid polymorphs contain distinct molecular struc-
tures, and that each molecular structure can propagate itself
(Bousset et al., 2013; Frederick et al., 2014; Gath et al., 2014;
Paravastu et al., 2008; Petkova et al., 2005). Self-propagating,
molecular-level polymorphism of amyloid fibrils is a likely under-
lying mechanism for the occurrence of distinct prion strains in
TSEs (Collinge and Clarke, 2007; Safar et al., 1998; Toyama
andWeissman, 2011; Wickner et al., 2010). As discussed below,
recent studies suggest that neurodegenerative diseases such as
AD, PD, and tauopathies (involving aggregation of the tau
protein) may exhibit variations in clinical characteristics and
neuropathology that are attributable to amyloid polymorphism,
in analogy to prion strains.
This article reviews recent work on amyloid formation, molec-
ular structure, and polymorphism that relates to the issues
described above. Several excellent reviews of relevant experi-
ments in cell cultures and animal models have appeared recently
(Ashe and Aguzzi, 2013; Guo and Lee, 2014; Hardy and Revesz,
2012; Jucker and Walker, 2013; Walker et al., 2013). Therefore,
this article focuses primarily on physical and structural proper-
ties of amyloid fibrils and related aggregates that could be thebasis for the biological phenomena. Although this article empha-
sizeswork on Ab, a-syn, and tau, similar ideas apply to other pro-
teins whose aggregation is associated with neurodegeneration.
It should also be noted that amyloid formation has been shown
to be a biologically functional, presumably evolved, property of
a variety of proteins (Pham et al., 2014).
Principles of Amyloid Formation from In Vitro Studies
Amyloid fibrils are typically 5–15 nm in width, unbranched,
straight over length scales approaching 1 micron, and often
many microns long. Measurements on bundles of aligned fibrils
by X-ray fiber diffraction first revealed that they contain
‘‘cross-b’’ structures (Eanes and Glenner, 1968), which are rib-
bon-like b sheets in which b strand segments run approximately
perpendicular to the fibril growth direction and hydrogen bonds
between b strands are approximately parallel to the growth di-
rection (Sunde et al., 1997). Figure 2 shows atomic models of
ideal cross-b structures, which can involve either parallel or anti-
parallel alignments of adjacent b strands. Figure 2 also shows
examples of double-layered cross-b structures, as may exist in
fibrils formed by peptides or proteins with two separate b strand
segments. As discussed below, a single amyloid fibril can
contain several cross-b subunits, with two or more b sheet layers
within each subunit. The spacing between b strands in a b sheet
is always 0.46–0.48 nm. Therefore, a one micron length of amy-
loid fibril typically contains thousands of protein molecules, with
the exact number depending on the number of cross-b subunits,
the number of b strand segments contributed to each cross-b
subunit by one molecule, and the number of b sheet layers within
each subunit.
In vitro, amyloid fibrils are readily prepared from purified syn-
thetic peptides or recombinant proteins by incubation in simpleNeuron 86, May 6, 2015 ª2015 Elsevier Inc. 633
Figure 3. Conceptual Representation of
Molecular Mechanisms for Amyloid
Formation
Starting with a peptide or protein monomer A, a
series of reversible monomer additions (orange
arrows) results in a transient oligomer B that can
undergo internal structural rearrangements (i.e.,
nucleation events, blue arrows) to form cross-b-like
structures C1 and C2. Subsequent monomer addi-
tions to C1 and C2 (red arrows) result in fibril poly-
morphs D1 and D2. Variations in growth conditions
can affect the relative nucleation rates or subse-
quent growth rates of the two polymorphs. Fibril
growth conditions can also affect the rates of fibril
fragmentation or secondary nucleation, favoring
one polymorph over the other. In real systems,
more than two fibril polymorphs can be formed by
the same peptide or protein. In addition, fibril
nucleation may compete with the formation of
‘‘off-pathway’’ aggregation intermediates (green
arrows), such as a metastable oligomer E and a
protofibril G, which grows from cross-b-like nucleus
F. Once formed, species D1, D2, E, and G remain in
dynamic equilibrium with monomers (or small olig-
omers), allowing a net transfer of peptide or protein
molecules from the less stable to the more stable
species.
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1,000 mM range. Under these conditions, fibrils appear on time
scales of minutes to days. In de novo preparations, the total fibril
mass often has a sigmoidal dependence on time, with a ‘‘lag
period’’ during which the fibril concentration remains too low to
be detectable, followed by a rapid rise in concentration to a
plateau level, at which the available protein in the solution has
been mostly consumed. Fibril growth mechanisms that can
lead to such a sigmoidal time-dependence have been investi-
gated by several groups (Chen et al., 2002; Cohen et al., 2013;
Knowles et al., 2009; Lomakin et al., 1997). A highly schematic
representation of the amyloid formation process, including poly-
morphism and ‘‘off-pathway’’ aggregation intermediates, is
given in Figure 3. Although many details remain uncertain, the
general picture is that the protein molecules self-associate tran-
siently into oligomers of various sizes during the lag period until
‘‘primary nucleation events’’ occur, corresponding to the forma-
tion of oligomers that are sufficiently stable and have appropriate
structures, allowing them to persist and grow into fibrils by the
addition of protein molecules to their ends.
Once a small concentration of fibrils has accumulated through
primary nucleation, additional fibrils can appear by fragmenta-634 Neuron 86, May 6, 2015 ª2015 Elsevier Inc.tion of existing fibrils or, as suggested
recently (Cohen et al., 2013), by ‘‘second-
ary nucleation’’ processes, which may
correspond to the initiation of new fibrils
along the sides of existing fibrils. The rapid
rise of fibril mass after the lag period oc-
curs when fragmentation or secondary
nucleation dominates the overall time
dependence of protein aggregation.
Amyloid fibril formation is sometimes
considered to be an irreversible process.
This is incorrect. Even after the mass offibrils reaches its plateau value, fibrils coexist with a low concen-
tration of soluble protein. Association and dissociation of protein
molecules continues to occur at fibril ends, with well-defined
‘‘on’’ and ‘‘off’’ rates as in any protein-protein or ligand-protein
binding process at thermal equilibrium. If fibrils are placed in a
solution that contains an excess of soluble protein, they grow.
Conversely, if fibrils are placed in a solution that contains a deficit
of soluble protein, they shrink until the concentration of soluble
protein reaches its equilibrium value (Qiang et al., 2013; Wetzel,
2006).
Self-propagation of amyloid fibrils is readily demonstrated
in vitro through seeded fibril growth. In this context, fibril ‘‘seeds’’
are short fibril fragments, usually created by sonication of long
‘‘parent’’ fibrils. When seeds are added to a solution of soluble
protein, the seeds grow into longer fibrils by addition of protein
molecules to their ends. The newly elongated fibrils can then
be sonicated to create a second generation of seeds, which
can be used in a second round of seeded growth. Fibrils that
grow from seeds generally inherit the morphologies (as revealed
by TEM) and molecular structures (as revealed by ssNMR) of
their parents (Bousset et al., 2013; Kodali et al., 2010; Petkova
et al., 2005).
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experiment, the lag period is abrogated and the fibril mass in-
creases linearly with time (Qiang et al., 2013; Wetzel, 2006).
Agitation or stirring of protein solutions is often found to accel-
erate the overall growth of fibrils in vitro. This effect is attributable
to fibril fragmentation by shear forces, which increases the con-
centration of fibril ends and hence the net rate of fibril growth.
The presence or absence of agitation can also influence the pre-
dominant fibril structures that develop (see below).
Self-propagation of prions or prion-like aggregates, such as
fibril seeds, is often described as a ‘‘templated conformational
conversion’’ process, in which the prion-like aggregates inevi-
tably ‘‘corrupt’’ the structures of soluble proteins they encounter
(Collinge and Clarke, 2007; Guo and Lee, 2014; Prusiner, 2013;
Walker et al., 2013). This description may be misleading,
because a net conversion of protein molecules from their solu-
ble state to their aggregated state (even if accompanied by a
conformational change) only occurs if the concentration of solu-
ble molecules exceeds its equilibrium value, i.e., if the solution is
supersaturated. Thus, observations that protein aggregation and
amyloid formation can be triggered within cells or in mammalian
tissue by introduction of exogenous aggregates (Eisele et al.,
2010; Frost et al., 2009a; Iba et al., 2013; Kfoury et al., 2012;
Langer et al., 2011; Luk et al., 2012a, 2012b; Meyer-Luehmann
et al., 2006; Sanders et al., 2014; Sto¨hr et al., 2012, 2014; Volpi-
celli-Daley et al., 2011; Watts et al., 2014) imply that the relevant
proteins are supersaturated in the intracellular or extracellular
compartments where aggregation occurs.
Fibril seeding is often highly sequence-specific. For example,
fibrils prepared in vitro from the islet amyloid polypeptide (IAPP)
do not act as efficient seeds for Ab40 fibrils, despite the similarity
of their core-forming sequences (O’Nuallain et al., 2004). Fibrils
formed in vitro by Ab40 or by the 42-residue Ab peptide (Ab42)
do not cross-seed one another efficiently (Lu et al., 2013). How-
ever, in certain cases, some of which may be biomedically
important (Giasson et al., 2003), efficient cross-seeding has
been reported. The factors that determine cross-seeding effi-
ciencies are not understood in detail but presumably have a mo-
lecular structural basis. Thus, cross-seeding efficiencies can be
polymorph-dependent, as exemplified by the dependence of
species barriers to prion infectivity on TSE strains (Jones and
Surewicz, 2005).
When fibrils are grown de novo under conditions that produce
a heterogeneous mixture of polymorphs, the relative populations
of different polymorphs can change in subsequent generations
that are produced by successive rounds of seeded growth (Para-
vastu et al., 2008). This is because different fibril structures can
have different self-propagation efficiencies, for example due to
different susceptibilities to fragmentation by sonication or due
to different intrinsic elongation rates. After many rounds, a nearly
homogeneous fibril sample can be created, possibly dominated
by a structure that was a minor component of the original parent
sample. The predominant structure can depend on the precise
details of the seeded growth protocol (Qiang et al., 2011).
Under typical in vitro conditions, various intermediate states of
protein aggregation are often observed by TEM or atomic force
microscopy (AFM), including assemblies that are roughly spher-
ical (Hoshi et al., 2003; Yu et al., 2009), assemblies that aredoughnut-shaped or pore-like (Lasagna-Reeves et al., 2011),
and assemblies called ‘‘protofibrils’’ that are fibril-like, but are
shorter and more highly curved than mature amyloid fibrils
(Goldsbury et al., 2005; Williams et al., 2005). Examples of
Ab40 aggregation intermediates are shown in Figure 1D. These
intermediates may develop during the lag period, before fibrils
appear in detectable quantities, and are generally less stable
thermodynamically thanmature amyloid fibrils. Nonetheless, un-
der certain conditions, aggregation intermediates can persist as
the predominant structural state for many hours or days, allow-
ing characterization of their structural properties and biological
effects (Ahmed et al., 2010; Chimon and Ishii, 2005; Chimon
et al., 2007; Kheterpal et al., 2006; Ladiwala et al., 2012; Lopez
del Amo et al., 2012; Qiang et al., 2012; Sandberg et al., 2010;
Sarkar et al., 2014; Scheidt et al., 2011, 2012; Tay et al., 2013).
Experiments from many laboratories provide evidence that
aggregation intermediates can be important neurotoxic species
in neurodegenerative diseases. Although it is sometimes stated
that amyloid fibrils are not toxic in cell cultures, experimental
results from several groups show that this is not true (Chimon
et al., 2007; Petkova et al., 2005; Qiang et al., 2012; Resende
et al., 2008; Xue et al., 2009). The apparent toxicity of fibrils in
cell cultures depends on their state of self-association and/or
their lengths, with sonicated fibrils being more toxic than long
fibrils that form entangled masses (Petkova et al., 2005; Xue
et al., 2009). The relationship between inherent cytotoxicity
and molecular structure (e.g., cross-b versus non-cross-b struc-
ture, parallel b sheet versus antiparallel b sheet structure) is not
yet clear. The possibility that fibril toxicity is attributable to
non-fibrillar assemblies that develop from fibrils in the culture
medium can be dismissed for several reasons: (1) in general,
more thermodynamically stable species do not spontaneously
evolve toward less stable species, (2) development of non-
fibrillar assemblies from fibrils is not observed in images of dis-
solving fibrils (Qiang et al., 2013), (3) non-fibrillar assemblies
are not detectable in spectroscopic and antibody-binding exper-
iments on short, cytotoxic fibril preparations (Xue et al., 2009).
In animal models, strong evidence exists that oligomeric
aggregates have adverse effects on neuronal function andmem-
ory (Lesne´ et al., 2006, 2013; Shankar et al., 2008; Walsh et al.,
2002). In the case of AD, immunohistochemical studies show
that certain oligomeric species exist in human brain tissue
(Kayed et al., 2003; Noguchi et al., 2009), although the molecular
structural properties of these species remain to be elucidated. At
least some of these species may be fibril fragments (Tomic et al.,
2009). In AD, it is conceivable that both fibrillar and non-fibrillar
aggregates contribute to neurodegeneration, perhaps through
different mechanisms. Recent progress on the structural charac-
terization of aggregation intermediates is discussed below.
Molecular Structural Basis for Amyloid Polymorphism
Whereas X-ray fiber diffraction patterns and TEM images pro-
vide important information about amyloid structures, one cannot
determine the molecular structures within amyloid fibrils or
even prove that well-defined, ordered structures exist based
on these data. In particular, the identities of b strand segments,
the types of b sheets (parallel versus antiparallel intermolecular
alignment), the nature of interactions between b sheet layers,Neuron 86, May 6, 2015 ª2015 Elsevier Inc. 635
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tural features cannot be determined. This information is available
from ssNMR measurements, which show that amyloid fibrils do
indeed contain well-defined molecular and supramolecular
structures (Bertini et al., 2011; Lu et al., 2013; Paravastu et al.,
2008; Petkova et al., 2006; Van Melckebeke et al., 2010). X-ray
crystallography of peptides that crystallize into cross-b struc-
tures also provides a wealth of detailed information about inter-
molecular interactions within such structures (Nelson et al.,
2005; Sawaya et al., 2007).
Molecular structural information is contained in several typesof
ssNMR measurements. NMR chemical shifts (i.e., the precise
values of NMR frequencies) have strong dependences on local
molecular conformation that can be analyzed by comparisons
with chemical shift databases for proteins with known structures
(Shen et al., 2009). Pairwise distances between atomic nuclei can
be determined precisely by quantitative measurements of
nuclear magnetic dipole-dipole couplings or approximately by
detection of ‘‘crosspeak’’ signals that connect the corresponding
pairs of NMR frequencies in multidimensional ssNMR spectra
(De Pae¨pe, 2012). Other types of ssNMR measurements can
also be used to obtain structural constraints at various length
scales (Franks et al., 2008; Sengupta et al., 2013). Strong, sharp
signals in ssNMR spectra arise from structurally ordered, rela-
tively rigid protein segments, while disordered and highly flexible
segments generally do not contribute to the ssNMR spectra (Van
Melckebeke et al., 2010). Thus, segments that comprise the core
structure of an amyloid fibril can be distinguished from flexible
loops or tails, which are generally outside the core. For protein
assemblies such as amyloid fibrils, ssNMR data are often com-
bined with constraints from electron microscopy or other sour-
ces. Computational approaches are then used to developmolec-
ular structural models that are consistent with the available data.
In the case of Ab fibrils, initial ssNMR studies focused on fi-
brils formed by nine-residue and 26-residue synthetic peptides
representing residues 34–42 (Ab34–42) and 10–35 (Ab10–35) of
full-length Ab (Benzinger et al., 1998; Lansbury et al., 1995).
The peptides were synthesized with 13C labels at specific carbon
sites, and ssNMR methods were used to determine specific
intermolecular and intramolecular distances among the labeled
carbon sites. Results for Ab34–42 indicated a cross-b structure
comprised of antiparallel b sheets (Lansbury et al., 1995); results
for Ab10–35 indicated a cross-b structure comprised of parallel b
sheets in which individual peptide molecules align with their
neighbors in an ‘‘in-register’’ manner (Benzinger et al., 1998).
These results were the first definite experimental indication
that cross-b motifs within fibrils formed by a given peptide or
protein have specific supramolecular structures and that struc-
tures within fibrils formed by different peptides can be qualita-
tively different from one another.
Subsequent ssNMR and EPR measurements on fibrils formed
in vitro by full-length Ab (Ab40 and Ab42) showed that these fi-
brils also contain in-register parallel b sheets (Antzutkin et al.,
2000, 2002; Balbach et al., 2002). Experiments by Petkova
et al. then showed that Ab40 fibril morphologies can be
controlled reproducibly by subtle variations in growth conditions
in vitro (Petkova et al., 2005). Specifically, Ab40 fibrils grown at
24C and pH7.4 with gentle agitation of the Ab40 solution during636 Neuron 86, May 6, 2015 ª2015 Elsevier Inc.the growth period have a predominant ‘‘striated ribbon’’
morphology (Figure 1A), whereas fibrils grown under the same
conditions except without agitation have a predominant
‘‘twisted’’ morphology (Figure 1B). Moreover, solid-state NMR
spectra of striated ribbons are obviously different from spectra
of twisted fibrils, with many differences in the 13C NMR chemical
shifts (i.e., the precise 13C NMR frequencies) of individual 13C-
labeled carbon sites (Petkova et al., 2005). Since NMR chemical
shifts are sensitive to local molecular conformation and struc-
tural environment, these results prove that distinct fibril morphol-
ogies correspond to distinct underlying molecular structures.
The number of distinct Ab40 fibril polymorphs is at least five, ac-
cording to subsequent studies, and may be on the order of ten
(Bertini et al., 2011; Kodali et al., 2010; Lu et al., 2013; Meinhardt
et al., 2009; Niu et al., 2014).
The molecular-level polymorphism observed in Ab40 fibrils
has also been observed in ssNMR studies of amyloid fibrils
formed by other disease-associated peptides and proteins,
including IAPP (Luca et al., 2007), a-syn (Bousset et al., 2013;
Comellas et al., 2011; Heise et al., 2005, 2008; Lemkau et al.,
2012), and tau (Andronesi et al., 2008; Daebel et al., 2012; Frost
et al., 2009b). Thus, in general, molecular structures within amy-
loid fibrils formed in vitro are not determined uniquely by the
amino acid sequences of amyloid-forming peptides and protein.
Instead, they are determined by the precise details of growth
conditions.
In principle, different fibril polymorphs can have different
spontaneous nucleation rates, extension rates, fragmentation
rates, and secondary nucleation rates, resulting in the observed
dependence of the predominant fibril morphology on growth
conditions. For Ab40, the predominance of striated ribbon fibrils
under agitated growth conditions is attributable in part to the
greater susceptibility of striated ribbons to fragmentation by
shear forces (Qiang et al., 2013).
Full molecular structural models for striated ribbon and twisted
Ab40 fibrils, shown in Figures 4A and 4B, were developed from
combinations of structural constraints from ssNMR and electron
microscopy (Paravastu et al., 2008; Petkova et al., 2006). These
models represent the first case in which specificmolecular struc-
tural features that differentiate one polymorph from another were
identified. Because striated ribbons contain variable numbers of
protofilaments (see Figure 1A), the model for striated ribbons
represents the structure of one protofilament. Somewhat sur-
prisingly, ssNMR data indicate that the peptide conformations
within the two polymorphs are quite similar, consisting of two b
strand segments (residues 10–22 and 30–40, roughly) that are
preceded by a disordered segment (residues 1–9) and separated
by a bend or loop (residues 23–29). The b strand segments
participate in separate parallel b sheets, which interact through
contacts among hydrophobic amino acid sidechains. The prin-
cipal difference between the two polymorphs is their overall sym-
metry, with the striated ribbon protofilament containing two
cross-b subunits, related by approximate 2-fold rotational sym-
metry about the fibril growth axis, and the twisted fibril containing
three cross-b units, related by approximate 3-fold rotational
symmetry. In addition, the detailed conformations of the bend
segments differ in the two polymorphs. The bend segment within
2-fold symmetric striated ribbon protofilaments is bridged by an
Figure 4. Molecular Structural Models for
Three Ab40 Fibril Polymorphs, Based on
Data from ssNMR and Electron Microscopy
(A) Fibrils grown in vitro with the striated ribbon
morphology, as in Figure 1A.
(B) Fibrils grown in vitro with the twisted
morphology, as in Figure 2B.
(C) Fibrils derived from brain tissue of a patient with
AD. In each case, the fibril structure is viewed in
cross-section, with the fibril growth direction
approximately perpendicular to the page.
Upper parts are cartoon representations, with
colors indicating the different cross-b subunits
within 2-fold symmetric (A) or 3-fold symmetric (B
and C) structures. Eight Ab40 molecules are shown
in each subunit. Lower parts are atomic represen-
tations, with one molecule in each subunit. Resi-
dues 9–40 are shown in (A) and (B). Residues 1–40
are shown in (C). Models in (A)–(C) are based on
PDB: 2LMN, 2LMP, 2M4J.
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of Asp23 and Lys28 (i.e., a salt bridge interaction). This interac-
tion is absent in 3-fold symmetric twisted fibrils.
At least two other Ab40 fibril polymorphs, grown under
different conditions and with different morphologies in TEM im-
ages, have been characterized subsequently by ssNMR. Fibrils
grown with vigorous agitation at 37C and pH8.5 are reported
to have a 2-fold symmetric structure, similar to that in
Figure 4A, but with somewhat different contacts among amino
acid sidechains within and between the two cross-b subunits
and with an additional b strand segment in the N-terminal tail
(Bertini et al., 2011). Fibrils grown with gentle agitation in the
presence of phospholipid vesicles at 37C and pH7.4 are re-
ported to contain a peptide conformation similar to the confor-
mations in Figures 4A and 4B, but with additional kinks at glycine
sites in residues 30–40 (Niu et al., 2014). A detailed structural
model for fibrils formed in vitro by the disease-associated
Glu22-deletion mutant of Ab40 has also been reported, accord-
ing to which the fibrils have 2-fold symmetry, parallel b sheets
within the two cross-b units, and a rather intricate conformation
for residues 21–40 (Schutz et al., 2014).
It therefore appears that, at least in the case of Ab40 fibrils,
different self-propagating polymorphs have closely related
structures, all of which contain in-register parallel b sheets and
essentially the same sets of residues on the exterior and in the
interior of the fibrils. The number of cross-b subunits can vary,
as can the conformations at certain residues, especially residues
that form non-b strand segments, as well as the extent of disor-
dered segments. Details of the packing of amino acid sidechains
in the interior are also variable.
While the ratio of Ab40 to Ab42 is typically around 5:1 in cere-
brospinal fluid of normal individuals (Spies et al., 2010), the insol-
uble Ab in AD brain tissue is often predominantly Ab42 (Gravina
et al., 1995). Full structural models for Ab42 fibrils based on
ssNMR data have not yet been published. Ab42 fibrils prepared
in vitro have similar morphologies to Ab40 fibrils, contain parallel
b sheets that interact through similar hydrophobic contacts, and
may also exist as both 2-fold symmetric and 3-fold symmetricpolymorphs (Antzutkin et al., 2002; Lu¨hrs et al., 2005; Olofsson
et al., 2007; Sato et al., 2006; To¨ro¨k et al., 2002).
Full structural models for a-syn and tau fibrils have also
not been published yet, although it is known that both a-syn and
tau fibrils contain in-register parallel b sheets (Chen et al., 2007;
Der-Sarkissian et al., 2003; Margittai and Langen, 2004), as do
amyloid fibrils formed by PrP, and other proteins (Bedrood et al.,
2012; Cobb et al., 2007; Helmus et al., 2011; Kryndushkin
et al., 2011; Ladner et al., 2010; Luca et al., 2007; Shewmaker
et al., 2006; Tycko et al., 2010; Wickner et al., 2008). Wild-type
a-syn fibrils prepared in vitro exhibit polymorphisms analogous
to those described above for Ab40 fibrils. As shown in
Figure 1C, distinct morphologies can be observed when fibrils
are grown under a single set of conditions (Heise et al., 2005).
With careful control of growth conditions, a single predominant
morphology can be created (Comellas et al., 2011). Wild-type
a-syn fibrils that resemble either striated ribbon or twisted
Ab40 fibrils in TEM images (despite the fact that a-syn is a sub-
stantially larger protein, containing 140 amino acids) can be
created by varying the ionic strength of the a-syn solution, with
other conditions being nominally identical (Bousset et al., 2013;
Gath et al., 2014). NMR and EPR data indicate that a-syn fibril
structures contain both rigid protein segments, which are pri-
marily b strands, and segments that remain disordered and flex-
ible. The locations and lengths of the rigid segments can vary
significantly among different polymorphs (Bousset et al., 2013;
Gath et al., 2014). Fibrils formed by disease-associated mutants
of a-syn have also been examined by ssNMR (Heise et al., 2008;
Lemkau et al., 2012, 2013). Structures of these fibrils are qualita-
tively similar to those formed by wild-type a-syn, but can have
somewhat different b strand lengths and locations.
Less is known about structural variations within full-length tau
fibrils, as ssNMR studies have been reported only for a 99-
residue tau construct called K19, which contains three of the
four possible repeat segments (R1, R3, and R4) from the
C-terminal portion of full-length tau. Polymorphism in K19 fibrils
has not been addressed explicitly, but two different studies of
K19 fibrils led to different conclusions regarding the extent ofNeuron 86, May 6, 2015 ª2015 Elsevier Inc. 637
Figure 5. Molecular Structural Models for Two Types of Aggregation
Intermediates
(A) Protofibrils formed by D23N-Ab40, viewed in cross-section, with the pro-
tofibril growth direction approximately perpendicular to the page. The cartoon
representation (upper part) shows eight D23N-Ab40 molecules in a double-
layered antiparallel cross-b structure identified by ssNMR, with alternating
colors to clarify the antiparallel alignment of adjacent molecules. The atomic
representation (lower part) shows two adjacent molecules.
(B) Cylindrin oligomer formed by the peptide KVKVLGDVIEV, which derives
from the amino acid sequence of aB-crystallin. In the cartoon representation
(upper part), the 3-fold symmetry axis of the cylindrin lies vertically in the page
and colors indicate different peptidemolecules within the hexameric structure.
The atomic representation (lower part) shows one pair of antiparallel mole-
cules. Models in (A) and (B) are based on PDB: 2LNQ, 3SGO.
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bel et al., 2012). In one study, the structured core of the fibrils
was found to contain only a single 18-residue segment, possibly
divided into three b strands that are separated by short bends
(Daebel et al., 2012). A similar phenomenon was seen in ssNMR
studies of fibrils formed by the Tyr145-Stop mutant of human
PrP, for which the structured core was found to contain only a
single 30-residue segment near the C terminus (Helmus et al.,
2008, 2010, 2011).
Experiments on tau fibrils formed in vitro have shown that fi-
brils prepared de novo from microtubule-binding regions of
wild-type tau or disease-associated mutants exhibit different
Fourier-transform infrared spectra, different degrees of suscep-
tibility to protease cleavage, and different susceptibilities to frag-
mentation (Aoyagi et al., 2007; Frost et al., 2009b; von Bergen
et al., 2000). When mutant fibrils are used to seed the growth
of wild-type fibrils, the resulting wild-type fibrils have the proper-
ties of the mutant fibril seeds (Frost et al., 2009b), showing that
structural variations are not attributable solely to amino acid
sequence variations.
Structures of Aggregation Intermediates
Figure 1D shows aggregation intermediates formed by Ab40
in vitro. Given that these intermediates have morphologies that
are qualitatively different from those of mature fibrils, one might
expect their molecular structures also to be qualitatively
different. Surprisingly, solid-state NMR data reported to date
for Ab40 and Ab42 intermediates, prepared under a variety of638 Neuron 86, May 6, 2015 ª2015 Elsevier Inc.conditions and exhibiting a variety of morphologies, indicate
that the peptide conformations within these intermediates are
rather similar to conformations within mature fibrils. In particular,
similar identities of b strand segments have been identified,
although the b strand segments may be shorter and the overall
degree of structural order is lower (Ahmed et al., 2010; Chimon
and Ishii, 2005; Chimon et al., 2007; Ladiwala et al., 2012; Lopez
del Amo et al., 2012; Qiang et al., 2012; Sarkar et al., 2014;
Scheidt et al., 2011, 2012; Tay et al., 2013). Evidence for parallel
intermolecular alignments has been obtained in the case of large
Ab40 oligomers with a spherical appearance in TEM images
(Chimon et al., 2007). In other cases, ssNMR data argue against
a parallel alignment (Ahmed et al., 2010; Tay et al., 2013) or indi-
cate conformational differences (Scheidt et al., 2011, 2012).
Detailed structural characterization of aggregation intermedi-
ates is complicated by their greater disorder (relative to mature
fibrils), their transient or unstable nature, and the difficulty of pre-
paring morphologically homogeneous samples. To date, only
one complete structural model for an Ab intermediate has been
reported, namely that of protofibrils formed by D23N-Ab40. In
this case, it was found that typical de novo fibril growth condi-
tions lead to a mixture of long, straight, mature fibrils (which
contain parallel b sheet structures similar to those in Figure 4)
and shorter, more highly curved protofibrils with anomalous
structures (Tycko et al., 2009). Protofibrils disappeared in
seeded growth experiments or when the original mixture was
sonicated, indicating the lower thermodynamic stability of proto-
fibrils relative to fibrils. Once a protocol for purifying the protofi-
brillar aggregates was devised, ssNMR and electronmicroscopy
measurements led to the structural model in Figure 5A (Qiang
et al., 2012). Remarkably, this D23N-Ab40 protofibril structure
contains a strand-bend-strand peptide conformation that
closely resembles the conformation in Ab40 fibrils. The same
sets of amino acid sidechains from the two b strand segments
interact through favorable hydrophobic contacts. However, the
two b strand segments form two separate layers of antiparallel
b sheets (as in Figure 2D), rather than the two layers of parallel
b sheets (as in Figure 2C) seen in mature fibrils.
Crystallographic studies of an 11-residue amyloid-forming
peptide from aB crystallin have produced the first atomic-reso-
lution structure of a small, nonfibrillar, oligomeric aggregation in-
termediate (Laganowsky et al., 2012). This structure, shown in
Figure 5B and termed a ‘‘cylindrin,’’ consists of six copies of
the peptide, arranged as three antiparallel b sheet dimers with
3-fold symmetry about a narrow central pore.
It is conceivable, although not yet proven, that the structures
in Figure 5 represent generic motifs for protofibrillar and nonfi-
brillar intermediates in amyloid formation. It is interesting that
both structures involve antiparallel b sheets, whereas the amy-
loid fibrils formed by proteins associated with neurodegenera-
tive diseases contain parallel b sheets. It is difficult to imagine
how conversion from antiparallel to parallel b sheets could
occur directly within an aggregated structure because this
would require disruption of numerous intermolecular hydrogen
bonds and would be disfavored by steric clashes within the
structure. Therefore, conversion of these aggregation intermedi-
ates to amyloid fibrils must involve dissociation of peptide mol-
ecules from the antiparallel structures, followed by their addition
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must be off-pathway intermediates. Under certain conditions,
they may form more quickly than amyloid fibrils and be suffi-
ciently stable to accumulate and become observable. However,
they appear to be structural side-products, rather than obligate
precursors to amyloid fibrils. Of course, this does not imply that
they are biologically irrelevant.
Intermediate structures that are qualitatively different from
those in Figure 5 can also exist, but have not been characterized
in detail yet. Some of these may involve parallel intermolecular
alignment (Chimonet al., 2007), and somemaybe ‘‘on-pathway,’’
i.e., able to convert directly to an amyloid structurewithout disso-
ciating. Ha¨rd and coworkers have proposed that certain Ab olig-
omers contain b-hairpins, based on their observation of a
b-hairpin conformation for Ab40 when bound to an antibody-
mimetic protein (Hoyer et al., 2008) and on the enhanced stability
of Ab40 andAb42 oligomerswhen intramolecular disulfide cross-
links are introduced in a manner that should stabilize b-hairpins
(Sandberg et al., 2010). While a b-hairpin conformation contains
two b strands, it differs from the Ab conformations in Figures
4A, 4B, and 5A in that the two b strands of a b-hairpin interact
through backbone hydrogen bonds (as in Figure 2E), rather
than through contacts among their sidechains.
Efforts to determine additional intermediate structures are un-
derway in many labs, and we can expect significant progress on
this problem in the near future. As one example, cryo-EM has
been used to elucidate the tubular structure of Ab42 protofibrils
that bind to PrP and exhibit PrP-dependent inhibition of long-
term potentiation (Nicoll et al., 2013). Information of a more qual-
itative nature about structures of aggregation intermediates has
also been obtained from experiments with conformation-depen-
dent antibodies that preferentially recognize certain classes of
structures (Kayed et al., 2003; Wu et al., 2010). These antibodies
have been used to identify the presence of both nonfibrillar
(Lasagna-Reeves et al., 2011) and fibrillar oligomers (Tomic
et al., 2009) in AD brain tissue.
Biological Significance of Structural Variations in
Amyloid Fibrils and Related Assemblies
Variations in the time course, clinical presentation, and neuropa-
thology of AD are known to exist (Karantzoulis and Galvin, 2011;
Lam et al., 2013). The same is true of PD and tauopathies (Dick-
son et al., 2010; Hughes et al., 1993; Schneider et al., 1997). Do
variations in the molecular structural details of amyloid fibrils or
aggregation intermediates play a role in the observed variations
in neurodegenerative disease development? It is well estab-
lished that structural variations in infectious PrP aggregates pro-
duce distinct TSE strains (Collinge and Clarke, 2007; Prusiner,
2013), although themolecular structures of infectious PrP aggre-
gates have not yet been characterized in detail. Different TSE
strains exhibit different incubation periods, different neuropa-
thology, different barriers to interspecies transmission, and
different clinical presentations. PrP aggregates from different
strains exhibit different patterns of proteolytic cleavage, different
degrees of resistance to denaturation, and different spectro-
scopic signatures (Caughey et al., 1998; Safar et al., 1998; Telling
et al., 1996). Prions of yeast also exhibit distinct ‘‘weak’’ and
‘‘strong’’ strains, characterized by different degrees of inactiva-tion of the corresponding yeast prion protein attributable to its
aggregation. Yeast prions are known to be amyloid fibrils
comprised of parallel b sheet structures (Kryndushkin et al.,
2011; Shewmaker et al., 2006; Taylor et al., 1999). Distinct
strains may arise from different combinations or lengths of
b-sheet-forming protein segments (Toyama et al., 2007).
In the context of AD, there are two separate parts to the ques-
tion of whether structural variations in aggregated Ab species
have biological effects. The first part is whether different classes
of Ab assemblies (i.e., fibrils, protofibrils, various types of oligo-
mers) have different effects. This is quite plausible because
different types of assemblies can contribute to neurodegenera-
tion throughdifferentmechanisms, suchasmembranedisruption
(Lasagna-Reeves et al., 2011), interaction with specific cell-sur-
face receptors (Nicoll et al., 2013), interference with synapse
function (Li et al., 2009), induction of inflammation (Cunningham,
2013), or generation of reactive oxygen species through metal
binding (Eskici and Axelsen, 2012). Although there is strong evi-
dence that nonfibrillar Ab aggregates have neurodegenerative
effects, the stereotypical spreading of neuropathology through
brain tissue in AD (Thal et al., 2002) and the ability of exogenous
Ab aggregates to induce neuropathology (Eisele et al., 2010;
Langer et al., 2011; Meyer-Luehmann et al., 2006; Morales
et al., 2012; Rosen et al., 2012; Sto¨hr et al., 2012, 2014; Watts
et al., 2014) strongly suggests that fibrillar aggregates are also
important, as fibrils have the intrinsic capacity to propagate
themselves through breakage and regrowth (i.e., through self-
seeding).
The second part of the question is whether the molecular-level
polymorphism of Ab fibrils discussed above is biologically signif-
icant. It is possible that the biological effects of all fibril poly-
morphs are nearly indistinguishable. However, one can readily
imagine how structural variations in amyloid fibrils might lead
to variations in biological effects, for example through struc-
ture-specific differences in interactions with cell membranes or
cell-surface receptors, differences in binding of metal ions, dif-
ferences in susceptibility to fragmentation and subsequent
transport through tissue, or differences in the structures of olig-
omeric species that may be derived from or coexist with the
fibrils. Although experimental evidence that amyloid fibril poly-
morphism is important in AD is not yet conclusive, several lines
of evidence now exist, as summarized in the following para-
graphs.
Ab fibril fragments have been shown to be toxic in primary
neuronal cell cultures at peptide concentrations above 1 mM
(Petkova et al., 2005; Qiang et al., 2012). A side-by-side compar-
ison of Ab40 fibrils prepared in vitro with either striated ribbon or
twisted morphologies and with similar lengths showed that the
twisted fibrils were significantly more toxic (Petkova et al.,
2005), possibly indicating differences in interactions with cell
membranes or cell-surface receptors.
Although detailed structural measurements by solid state
NMR or related methods cannot be performed directly on amy-
loid fibrils in brain tissue, such measurements can be performed
on fibrils that are prepared by seeded growth from amyloid-con-
taining tissue. Seeded growth amplifies the quantity of fibrils to
the milligram scale required for ssNMR and allows the introduc-
tion of the necessary 13C and 15N labels (Paravastu et al., 2009).Neuron 86, May 6, 2015 ª2015 Elsevier Inc. 639
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scopy data for Ab40 fibrils seeded with amyloid-enriched extract
from brain tissue of two patients with AD and different clinical
histories (Lu et al., 2013). For each patient individually, the data
indicated a single predominant fibril structure throughout the
cerebral cortex. However, ssNMR spectra of fibrils derived
from brain tissue of the two patients were clearly different, indi-
cating different predominant structures in the two patients. For
one of the patients, an extensive set of ssNMR data was ob-
tained, leading to the detailed molecular structural model shown
in Figure 4C. This structure is similar to the 3-fold-symmetric
structure of twisted Ab40 fibrils prepared in vitro (Figure 4B),
but contains the Asp23-Lys28 salt bridge of striated ribbon fibrils
(Figure 4A), has a structurally ordered N-terminal segment, and
includes a more intricate conformation for residues 30–40 than
observed in twisted or striated ribbon fibrils. A full structural
model for brain-seeded Ab40 fibrils from the second patient
with AD has not yet been reported, but the published data indi-
cate a 3-fold-symmetric structure with specific differences in
peptide backbone conformation and inter-residue contacts rela-
tive to the model in Figure 4C (Lu et al., 2013). These results
establish the important facts that individual AD patients can
develop structurally homogeneous Ab fibrils in their cortical tis-
sue (despite the pronounced propensity for polymorphism indi-
cated by in vitro experiments) and that different patients can
develop different fibril structures. Further experiments are
required to establish definite correlations between fibril structure
and clinical history. In addition, it has not yet been shown that
observations for brain-seeded Ab40 fibrils can be extended to
fibrils formed by Ab42.
Further evidence for possible effects of Ab fibril structure on
disease development comes from experiments with transgenic
(Tg) mice that overexpress the human amyloid precursor protein
(APP), from which Ab peptides are generated. In ground-
breaking experiments, Walker and colleagues showed that the
development of amyloid plaques in cortical tissue of these
mice can be accelerated by injection of exogenous amyloid-
containing material, either into the brain or elsewhere in the
body (Eisele et al., 2010; Langer et al., 2011; Meyer-Luehmann
et al., 2006). Thus, Ab aggregates can exhibit prion-like infec-
tivity, at least under laboratory conditions. Moreover, in experi-
ments in which brain homogenates from AD patients or from
two different Tg mouse lines were used, it was found that the
patterns of amyloid deposition were dependent on the source
of the brain homogenate, suggesting that different homogenates
contained different fibril structures that propagated differently
through the brain tissue of the recipient mice (Meyer-Luehmann
et al., 2006).
Recent experiments by Prusiner and colleagues (Sto¨hr et al.,
2012, 2014) have shown that amyloid deposition in Tg mice
can be induced not only by injection of amyloid-containing brain
homogenates or extracts, but also by injection of synthetic Ab
fibrils. Differences in Ab plaque sizes and densities were noted,
depending on the conditions under which the synthetic Ab fibrils
were prepared and thus presumably on the molecular structures
of the injected fibrils. Additional experiments on Tg mice using
brain homogenates from patients with familial AD (Watts et al.,
2014) revealed differences in the morphologies of the induced640 Neuron 86, May 6, 2015 ª2015 Elsevier Inc.amyloid deposits around cerebral blood vessels and in the
relative proportions of 38-residue, 40-residue, and 42-residue
Ab components in these deposits, depending on the nature of
the genetic mutations carried by the patients.
Experiments described above used Tg mice that eventually
develop Ab plaques spontaneously, although the appearance
of plaques is accelerated significantly by injection of the exoge-
neous Ab-containing material. It has also been shown that injec-
tion of AD brain homogenate can induce plaque formation in Tg
mice and Tg rats that do not develop plaques within their normal
life spans (Morales et al., 2012; Rosen et al., 2012).
Related evidence that amyloid polymorphism can have biolog-
ical significance has been reported for both a-syn and tau fibrils.
Experiments by Diamond and colleagues have shown that intra-
cellular aggregation of tau in cell cultures is inducible by exoge-
nous tau fibrils contained in liposomes and persists through
many cycles of cell division (Frost et al., 2009a; Kfoury et al.,
2012). Cells exposed to exogenous tau fibrils were found to
contain distinct sizes of tau aggregates with distinct patterns
of proteolysis, representing distinct prion-like strains. Cell ly-
sates were then used to induce tau aggregation in brains of Tg
mice, with different lysate strains producing different patterns
of tau deposition and microglia activation in the brain tissue
(Sanders et al., 2014). These neuropathologic differences in the
mice were propagated through several passages. Tau aggrega-
tion in Tg and wild-type mice can also be induced by injection of
brain homogenates from human patients with various tauopa-
thies. The resulting tau lesions in the mouse brains exhibit varia-
tions that correlate with neuropathologic variations in the original
human tissue (Clavaguera et al., 2013).
In the case of a-syn, polymorphs similar to the twisted and stri-
ated ribbon polymorphs of Ab40 fibrils can be prepared in vitro
by growing the a-syn fibrils in buffers with either low or high ionic
strengths (Bousset et al., 2013). The two polymorphs have
different antibody-binding properties and (according to ssNMR
data) different combinations of structurally ordered and disor-
dered segments (Gath et al., 2014). Both polymorphs can induce
intracellular aggregation of a-syn in neuronal cell cultures, but
with different rates and different degrees of self-propagation
stability.
Intracellular a-syn fibril formation in primary neuronal cell cul-
tures frommice and rats has been shown to occur after exposure
to sonicated fibril fragments formed by full-length recombinant
human a-syn or by truncated constructs containing the central
hydrophobic segment of a-syn (Volpicelli-Daley et al., 2011). It
is not known whether the induced intracellular a-syn fibrils
have the same structures in all cases. In these experiments,
exogenous fibril fragments were found to enter the neurons by
adsorptive endocytosis, initially producing intracellular aggrega-
tion in axons and subsequently leading to the appearance of
a-syn fibrils in cell bodies and dendrites. When pre-formed re-
combinant fibrils were injected into wild-type mouse brains,
aggregated a-syn was found to spread from the injection site
exclusively to axonally connected brain regions (Luk et al.,
2012a).
Although cross-seeding of amyloid fibril formation is generally
inefficient between proteins with different amino acid se-
quences, a-syn and tau fibrils have been shown to cross-seed
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brils are grown de novo under certain conditions, these fibrils
do not induce intracellular tau aggregation in cultured neurons.
However, after ten rounds of seeded growth, the resulting
a-syn fibrils do induce intracellular tau aggregation, presumably
due to preferential amplification of a specific a-syn fibril structure
by repeated seeding as discussed above (Guo et al., 2013).
Indeed, infrared and circular dichroism spectra of the seeded
fibrils were found to differ from spectra of the de novo fibrils,
as did their protease digestion patterns. When the same fibrils
were injected into Tgmice that overexpress a human taumutant,
accelerated tau aggregation was observed only with the seeded
a-syn fibrils, indicating a significant structurally based difference
in pathological cross-seeding efficiencies within brain tissue.
Conclusions
Our understanding of amyloid fibril structures and structural var-
iations has advanced substantially in recent years, due to infor-
mation from ssNMR and other novel experimental approaches.
Structures of various classes of aggregation intermediates are
now being elucidated. Although the existence of significant
correlations between variations in molecular structural features
and variations in neurodegenerative diseases in humans has
not been proven, this possibility now seems quite plausible
and worth pursuing in future studies. Such correlations would
have a variety of implications. For example, definite correlations
between variations in Ab fibril structures and variations in the
severity of cognitive impairment or progression rate of AD would
support the idea that fibrils are not devoid of clinically significant
neurotoxic effects (Che´telat et al., 2012). One argument against a
significant role for Ab fibrils in AD stems from observations that
variations in cognitive impairment do not correlate strongly
with variations in the total quantity of amyloid material in cortical
tissue in AD patients (Giannakopoulos et al., 2003) and that am-
yloid can develop in asymptomatic elderly people in quantities
similar to (but generally less than) those in patients with AD (Ai-
zenstein et al., 2008). This argument does not take into account
the fact that different predominant Ab fibril structures can
develop in different patients (Lu et al., 2013), which may have
different neurotoxic and cognitive effects.
Correlations between variations in amyloid fibril structure and
patient-to-patient variations in neurodegenerative diseases
would make the development of structure-specific amyloid im-
aging agents an important goal. Compounds for positron emis-
sion tomography (PET) that bind to Ab plaques are now used
in research and clinical practice (Fleisher et al., 2011; Klunk
et al., 2004). The molecular-level binding sites for these com-
pounds have not yet been identified. For Pittsburgh Compound
B, the number of high-affinity binding sites per Ab molecule
has been reported to be greater than 0.5 for Ab deposits in hu-
man brain tissue, but approximately 0.001 for Ab deposits in
Tg mouse brains and less than 0.001 for synthetic Ab fibrils
(Klunk et al., 2005). If certain Ab40 and Ab42 fibril structures
are found in patients who experience progression from mild
cognitive impairment (MCI) to AD, whereas other structures are
found in patients with non-progressing MCI or in asymptomatic
elderly people, then PET scanning agents that bind selectively
to the AD-related structures would be highly desirable.Finally, although it may be difficult to prevent the age-related
accumulation of Ab fibrils and other aggregates in brain tissue,
it is conceivable that compounds can be developed to direct
the aggregation process away from specific structures and to-
ward others. If certain structures lead to neurodegeneration
most aggressively, then compounds that prevent formation of
those specific structures could be used to prevent or limit neuro-
degeneration.
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